Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Diuretics/therapeutic use , Endothelium, Vascular/physiopathology , Hypertension/drug therapy , Peptidyl-Dipeptidase A/blood , Vasodilation/physiology , Adult , Biomarkers/blood , Blood Pressure/physiology , Brachial Artery/diagnostic imaging , Brachial Artery/drug effects , Brachial Artery/physiopathology , Drug Therapy, Combination , Endothelium, Vascular/drug effects , Female , Humans , Hydrochlorothiazide/therapeutic use , Hypertension/enzymology , Hypertension/physiopathology , Male , Middle Aged , Perindopril/therapeutic use , Severity of Illness Index , Treatment Outcome , Ultrasonography, DopplerABSTRACT
UNLABELLED: The development of arterial hypertension is accompanied by impairment of the normal ratio of the "ACE-depending" and of the sympathetic nervous system, correlates with the action on the main pharmacological "targets": I-I-imidazoline receptors (moxonidine) or the ACE activity (enalapril). The aim of the present investigation was to determine the hypotensive and metabolic effects of moxonidine and enalapril depending on the basal ACE activity in patients with arterial hypertension, complicated with the metabolic syndrome. Effectiveness of moxonidine and enalapril administration (during 24 weeks) depended on the basal ACE activity in the hypertensive patients: (a) in the group of patients with low basal ACE activity moxonidine very effectively decreased systolic and diastolic blood pressure, compared with the group of patients with high basal ACE activity; (b) influence of enalapril on the level of arterial blood pressure was more pronounced with high basal ACE activity. IN CONCLUSION: choosing a hypotensive treatment for patients with the metabolic syndrome, it is advisable to take into account the basal ACE activity levels.
